DILI懸念を検出するためのin vitroスクリーニングプロセスの自社化合物を用いた遡及的分析
-
- 宮本 実
- 武田薬品工業株式会社薬剤安全性研究所
-
- 天野 雄一郎
- 武田薬品工業株式会社薬剤安全性研究所
-
- 穴山 久志
- 武田薬品工業株式会社薬剤安全性研究所
-
- Yvonne P DRAGAN
- Drug Safety Research and Evaluation, Takeda Pharmaceuticals International, Inc.
書誌事項
- タイトル別名
-
- Retrospective analysis of the in vitro screening process for detecting DILI liability using Takeda legacy compounds
抄録
<p>Drug-induced liver injury (DILI) is a significant public health problem that has a critical impact on not only patients but also healthcare professionals, pharmaceutical companies and regulatory authorities. It is considered difficult to predict its occurrence due to a complex interaction between chemical properties and patient factors.</p><p>Recent technological advances have led to the development of in vitro assays that can improve the predictability of clinical adverse events, and they are now becoming available in the early stages of drug discovery. Based on the concept of "Safety by Design", we have adopted a tiered approach that is stepwise approach from "a simple and high-throughput assay system" to "a complex assay system focused on organ toxicity". </p><p>Recently we re-evaluated Takeda legacy compounds including lapaquistat which has been terminated in phase III due to safety concerns in the liver, by the DILI-related assays introduced in the tiered approach, as part of evaluation of the usefulness of these assays for DILI prediction.</p><p>In this symposium, we will report the results and would like to discuss the future challenge to improve the predictability of clinical DILI.</p>
収録刊行物
-
- 日本毒性学会学術年会
-
日本毒性学会学術年会 47.1 (0), S18-4-, 2020
日本毒性学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390848647545152384
-
- NII論文ID
- 130007898476
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可